RU98103395A - HUMAN PROTEIN MP52 ARG - Google Patents

HUMAN PROTEIN MP52 ARG

Info

Publication number
RU98103395A
RU98103395A RU98103395/13A RU98103395A RU98103395A RU 98103395 A RU98103395 A RU 98103395A RU 98103395/13 A RU98103395/13 A RU 98103395/13A RU 98103395 A RU98103395 A RU 98103395A RU 98103395 A RU98103395 A RU 98103395A
Authority
RU
Russia
Prior art keywords
protein
pharmaceutical composition
composition according
seq
host cell
Prior art date
Application number
RU98103395/13A
Other languages
Russian (ru)
Inventor
Кимура Митио
Мацумото Томоаки
Такахаси Микико
Кавай Синдзи
Фудзино Юкио
Original Assignee
Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх filed Critical Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх
Publication of RU98103395A publication Critical patent/RU98103395A/en

Links

Claims (6)

1. Белок, состоящий из аминокислот 1-121 SEQ ID NО:l из прилагаемого Списка Последовательностей.1. A protein consisting of amino acids 1-121 of SEQ ID NO: l from the attached List of Sequences. 2. Способ получения биологически-активного белка по п.1, где, по крайней мере, часть ДНК-последовательности, представленной в последовательности SEQ ID NО:l, интродуцирована в подходящую клетку-хозяина в условиях, которые обеспечивают экспрессию ДНК-последовательности и образование белка, с последующим отделением указанного белка от других белков, продуцируемых указанной клеткой-хозяином. 2. The method of obtaining the biologically active protein according to claim 1, where at least part of the DNA sequence represented in the sequence of SEQ ID NO: l is introduced into a suitable host cell under conditions that allow expression of the DNA sequence and the formation of protein, followed by separation of said protein from other proteins produced by said host cell. 3. Фармацевтическая композиция, содержащая в качестве активного вещества белок по п. 1, при необходимости вместе с обычными веществами носителями, дополнительными веществами, разбавителями и наполнителями. 3. A pharmaceutical composition containing, as an active substance, a protein according to claim 1, optionally together with conventional carriers, additional substances, diluents and excipients. 4. Применение фармацевтической композиции по п. 3, для стимулирования костного морфогенеза, лечения или предупреждения повреждения костей, хрящей, соединительных тканей, кожи, слизистых мембран, эпителия или зубов и для использования в зубных имплантатах, и для использования в способах лечения ран и регенерации тканей. 4. The use of the pharmaceutical composition according to claim 3, for stimulating bone morphogenesis, treating or preventing damage to bones, cartilage, connective tissues, skin, mucous membranes, epithelium or teeth and for use in dental implants, and for use in methods of treating wounds and regeneration tissues. 5. Применение фармацевтической композиции по п. 3 для лечения остеопороза или костных переломов. 5. The use of the pharmaceutical composition according to claim 3 for the treatment of osteoporosis or bone fractures. 6. Фармацевтическая композиция по п. 3 для использования в ортопедической реконструкции, костной трансплантации, косметической хирургии или зубной имплантации. 6. The pharmaceutical composition according to claim 3 for use in orthopedic reconstruction, bone transplantation, cosmetic surgery or dental implantation.
RU98103395/13A 1995-08-03 1996-08-02 HUMAN PROTEIN MP52 ARG RU98103395A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE95112241.5 1995-08-03
EP95112241.5 1995-08-03

Publications (1)

Publication Number Publication Date
RU98103395A true RU98103395A (en) 2000-02-27

Family

ID=

Similar Documents

Publication Publication Date Title
Cook Preclinical and clinical evaluation of osteogenic protein-1 (BMP-7) in bony sites
JP2869381B2 (en) Osteogenic device
US5364839A (en) Osteoinductive pharmaceutical formulations
Kim et al. Role of BMP, βig-h3, and chitosan in early bony consolidation in distraction osteogenesis in a dog model
KR0175138B1 (en) Composition inducing a binding
US7268114B2 (en) Protein and process for preparing the same
ATE295734T1 (en) USE OF FIBROBLAST GROWTH FACTOR ANALOGUES TO STIMULATE BONE GROWTH
ATE269102T1 (en) USE OF FIBROBLAST GROWTH FACTORS TO STIMULATE BONE GROWTH
DE69813908D1 (en) USE OF CREATINE SUBSTANCES FOR TREATING BONE AND CARTILAGE CELLS AND TISSUE
RU2180234C2 (en) Materials stimulating cartilage/bone growth for producing preparations
Jacobsen Periosteum: its relation to pediatric fractures
WO2017101026A1 (en) Composition of mussel adhesive protein and growth factor
JP2001131086A (en) Composition for promoting repair of connective tissue, containing endothelin, and use of endothelin in preparation of the composition
JP2001527030A (en) Osteopontin-based composition for improving bone repair effect
US5830859A (en) Complex for inducing bone growth in the maxillary sinus
RU98103395A (en) HUMAN PROTEIN MP52 ARG
CN1844391A (en) Nucleotide sequence for human morphogenetic protein 9 recombinant proteins and production method and use thereof
RU2155561C2 (en) Method for setting intraorganic polymer endoprosthesis of the talocrural joint
NZ320721A (en) Use of the S-100b protein as a medicine to treat amyotrophic lateral sclerosis or multiple sclerosis
RU98103339A (en) NEW HMW HUMAN MP52-PROTEINS
RU2172146C1 (en) Method for treating the cases of not united fracture or false articulations of long bones
Uwagie et al. Use of native bovine bone morphogenetic protein extract in healing segmental tibial bone defects in goats.
RU2193868C2 (en) Method for stimulation of reparative osteogenesis
RU2225212C2 (en) Method for stimulating distraction regenerate
KR950703993A (en) Periodontal tissue disease treatment (PERIODONAL DISEASE REMEDY)